Biosimilars in Europe
This reprint examines regulatory, pricing and reimbursement issues related to the market access and uptake of off-patent biologics, biosimilars, next-generation biologics and competing innovative medicines in European countries.
I tiakina i:
| Hōputu: | Online |
|---|---|
| Reo: | Ingarihi |
| I whakaputaina: |
MDPI - Multidisciplinary Digital Publishing Institute
2023
|
| Ngā marau: | |
| Urunga tuihono: | ONIX_20230202_9783036565750_185 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|
| _version_ | 1869524391205797888 |
|---|---|
| collection | Directory of Open Access Books |
| description | This reprint examines regulatory, pricing and reimbursement issues related to the market access and uptake of off-patent biologics, biosimilars, next-generation biologics and competing innovative medicines in European countries. |
| format | Online |
| id | doab-20.500.12854ir-96784 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2023 |
| publishDateRange | 2023 |
| publishDateSort | 2023 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-967842024-03-31T13:10:25Z Biosimilars in Europe Vulto, Arnold G. Simoens, Steven Huys, Isabelle infliximab etanercept TNFα inhibitors biologics biosimilars Germany policies incentives uptake market dynamics biosimilar market biosimilar/supply and distribution biosimilar sustainability Delphi technique pricing reimbursement utilization biosimilar biological information education communication patient Europe adalimumab biosimilarity assessment quality attributes (QAs) potentially critical quality attributes (pCQAs) European public assessment reports (EPARs) clinical governance Spain barriers regulatory review approval clinical queries regulatory science budget impact analysis savings pharmaceutical spending cost containment reference biological competitive market Belgium trastuzumab intravenous subcutaneous HER2-positive breast cancer drug costs healthcare costs cost simulation tender procurement off-patent award criteria switching interchangeability sustainability competition n/a thema EDItEUR::M Medicine and Nursing thema EDItEUR::K Economics, Finance, Business and Management::KN Industry and industrial studies::KND Manufacturing industries This reprint examines regulatory, pricing and reimbursement issues related to the market access and uptake of off-patent biologics, biosimilars, next-generation biologics and competing innovative medicines in European countries. 2023-02-02T16:51:15Z 2023-02-02T16:51:15Z 2023 book ONIX_20230202_9783036565750_185 9783036565750 9783036565743 https://directory.doabooks.org/handle/20.500.12854/96784 eng image/jpeg Attribution 4.0 International https://mdpi.com/books/pdfview/book/6730 https://mdpi.com/books/pdfview/book/6730 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-0365-6574-3 10.3390/books978-3-0365-6574-3 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783036565750 9783036565743 188 Basel open access |
| spellingShingle | infliximab etanercept TNFα inhibitors biologics biosimilars Germany policies incentives uptake market dynamics biosimilar market biosimilar/supply and distribution biosimilar sustainability Delphi technique pricing reimbursement utilization biosimilar biological information education communication patient Europe adalimumab biosimilarity assessment quality attributes (QAs) potentially critical quality attributes (pCQAs) European public assessment reports (EPARs) clinical governance Spain barriers regulatory review approval clinical queries regulatory science budget impact analysis savings pharmaceutical spending cost containment reference biological competitive market Belgium trastuzumab intravenous subcutaneous HER2-positive breast cancer drug costs healthcare costs cost simulation tender procurement off-patent award criteria switching interchangeability sustainability competition n/a thema EDItEUR::M Medicine and Nursing thema EDItEUR::K Economics, Finance, Business and Management::KN Industry and industrial studies::KND Manufacturing industries Biosimilars in Europe |
| title | Biosimilars in Europe |
| title_full | Biosimilars in Europe |
| title_fullStr | Biosimilars in Europe |
| title_full_unstemmed | Biosimilars in Europe |
| title_short | Biosimilars in Europe |
| title_sort | biosimilars in europe |
| topic | infliximab etanercept TNFα inhibitors biologics biosimilars Germany policies incentives uptake market dynamics biosimilar market biosimilar/supply and distribution biosimilar sustainability Delphi technique pricing reimbursement utilization biosimilar biological information education communication patient Europe adalimumab biosimilarity assessment quality attributes (QAs) potentially critical quality attributes (pCQAs) European public assessment reports (EPARs) clinical governance Spain barriers regulatory review approval clinical queries regulatory science budget impact analysis savings pharmaceutical spending cost containment reference biological competitive market Belgium trastuzumab intravenous subcutaneous HER2-positive breast cancer drug costs healthcare costs cost simulation tender procurement off-patent award criteria switching interchangeability sustainability competition n/a thema EDItEUR::M Medicine and Nursing thema EDItEUR::K Economics, Finance, Business and Management::KN Industry and industrial studies::KND Manufacturing industries |
| topic_facet | infliximab etanercept TNFα inhibitors biologics biosimilars Germany policies incentives uptake market dynamics biosimilar market biosimilar/supply and distribution biosimilar sustainability Delphi technique pricing reimbursement utilization biosimilar biological information education communication patient Europe adalimumab biosimilarity assessment quality attributes (QAs) potentially critical quality attributes (pCQAs) European public assessment reports (EPARs) clinical governance Spain barriers regulatory review approval clinical queries regulatory science budget impact analysis savings pharmaceutical spending cost containment reference biological competitive market Belgium trastuzumab intravenous subcutaneous HER2-positive breast cancer drug costs healthcare costs cost simulation tender procurement off-patent award criteria switching interchangeability sustainability competition n/a thema EDItEUR::M Medicine and Nursing thema EDItEUR::K Economics, Finance, Business and Management::KN Industry and industrial studies::KND Manufacturing industries |
| url | ONIX_20230202_9783036565750_185 |